SG10201602434UA - Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus - Google Patents

Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus

Info

Publication number
SG10201602434UA
SG10201602434UA SG10201602434UA SG10201602434UA SG10201602434UA SG 10201602434U A SG10201602434U A SG 10201602434UA SG 10201602434U A SG10201602434U A SG 10201602434UA SG 10201602434U A SG10201602434U A SG 10201602434UA SG 10201602434U A SG10201602434U A SG 10201602434UA
Authority
SG
Singapore
Prior art keywords
rsv
vaccine
respiratory syncytial
syncytial virus
nanoparticle
Prior art date
Application number
SG10201602434UA
Other languages
English (en)
Inventor
Gale Smith
Yingyun Wu
Michael Massare
Ye Liu
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of SG10201602434UA publication Critical patent/SG10201602434UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201602434UA 2011-09-30 2012-09-27 Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus SG10201602434UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161542040P 2011-09-30 2011-09-30
US201161542721P 2011-10-03 2011-10-03
US201261611834P 2012-03-16 2012-03-16
US201261614286P 2012-03-22 2012-03-22

Publications (1)

Publication Number Publication Date
SG10201602434UA true SG10201602434UA (en) 2016-05-30

Family

ID=47996397

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201602434UA SG10201602434UA (en) 2011-09-30 2012-09-27 Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
SG11201400999VA SG11201400999VA (en) 2011-09-30 2012-09-27 Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201400999VA SG11201400999VA (en) 2011-09-30 2012-09-27 Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus

Country Status (14)

Country Link
US (4) US20130122032A1 (ru)
EP (1) EP2760469A4 (ru)
JP (1) JP2014530010A (ru)
KR (1) KR20140077169A (ru)
CN (2) CN104080476A (ru)
AU (1) AU2013201495B2 (ru)
BR (1) BR112014007616A2 (ru)
CA (1) CA2849471A1 (ru)
HK (1) HK1222125A1 (ru)
IL (1) IL231637A0 (ru)
MX (1) MX2014003777A (ru)
RU (1) RU2014117068A (ru)
SG (2) SG10201602434UA (ru)
WO (1) WO2013049342A1 (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3067064T (lt) 2008-12-09 2020-09-10 Novavax, Inc. Modifikuoti rsv f baltymai ir jų panaudojimo būdai
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
BR112015025392A2 (pt) * 2013-04-08 2017-10-10 Medimmune Llc composição de vacina e método de utilização
JP2016533332A (ja) * 2013-09-24 2016-10-27 マサチューセッツ インスティテュート オブ テクノロジー 自己集合型ナノ粒子ワクチン
CN105087643A (zh) * 2014-04-16 2015-11-25 中国科学院上海巴斯德研究所 重组表达人呼吸道合胞病毒f1蛋白胞外区的方法及表达系统
US10100372B2 (en) 2014-06-18 2018-10-16 Georgia State University Research Foundation, Inc. Recombinant RSV reporter virus
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
US11324816B2 (en) 2015-08-31 2022-05-10 Technovax, Inc. Human respiratory syncytial virus (HRSV) virus-like particles (VLPS) based vaccine
CA2997181A1 (en) * 2015-09-02 2017-03-09 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
EP3344291A4 (en) * 2015-09-03 2019-04-10 Novavax, Inc. VACCINE COMPOSITIONS WITH IMPROVED STABILITY AND IMMUNOGENICITY
CN106547635B (zh) 2015-09-18 2020-10-09 阿里巴巴集团控股有限公司 一种作业的操作重试方法和装置
BR112018010805A2 (pt) 2015-12-23 2018-11-27 Pfizer Inc. mutantes de proteína f de rsv
CN106124767A (zh) * 2016-05-12 2016-11-16 广州瑞辉生物科技股份有限公司 呼吸道合胞病毒IgA抗体检测试纸条及其检测方法
WO2018067300A1 (en) * 2016-10-03 2018-04-12 University Of Massachusetts Methods for immunizing pre-immune subjects against respiratory syncytial virus (rsv)
IL269258B2 (en) 2017-03-15 2023-09-01 Novavax Inc Methods and compositions for inducing immune responses against Clostridium difficile
MX2019011869A (es) 2017-04-04 2020-01-09 Univ Washington Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso.
CN107050446B (zh) * 2017-04-19 2020-08-11 武汉博沃生物科技有限公司 经修饰的季节流感-rsv联合疫苗及其制备方法
WO2019063844A1 (en) * 2017-09-29 2019-04-04 Universiteit Antwerpen VACCINATION AGAINST SYNCYTIAL RESPIRATORY VIRUS
US11771755B2 (en) 2018-02-28 2023-10-03 University Of Washington Self-asssembling nanostructure vaccines
KR20210004959A (ko) 2018-03-19 2021-01-13 노바백스, 인코포레이티드 다가 인플루엔자 나노입자 백신
WO2020076141A1 (ko) * 2018-10-12 2020-04-16 에스케이바이오사이언스 주식회사 재조합 rsv 생백신주 및 이의 제조 방법
WO2020092365A1 (en) * 2018-10-29 2020-05-07 Binh Ha Rsv virus-like particles and methods of use thereof
KR20200050264A (ko) * 2018-11-01 2020-05-11 에스케이바이오사이언스(주) 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물
WO2020175660A1 (ja) * 2019-02-28 2020-09-03 Ｋｍバイオロジクス株式会社 Ｒｓｖ ｆ／ｇキメラワクチン
CN110229219B (zh) * 2019-06-21 2021-03-30 中国科学院武汉病毒研究所 一种新型的呼吸道合胞病毒疫苗抗原的制备方法及其用途
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
AU2021214064A1 (en) * 2020-01-27 2022-08-18 Novavax, Inc. Coronavirus vaccine formulations
CN113855796B (zh) * 2021-07-30 2024-01-26 河北医科大学 卡介苗作为呼吸道合胞病毒灭活疫苗佐剂的应用
TW202330922A (zh) * 2021-11-19 2023-08-01 美商Ｒｎａ免疫公司 核糖核酸呼吸道融合病毒(rsv)疫苗之組合物及方法
WO2024050015A1 (en) * 2022-09-01 2024-03-07 Novavax, Inc. Downstream process for purification of viral proteins with hydrophobic membrane domain for use in vaccine compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027825A2 (en) * 2003-04-25 2005-03-31 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
CA2684578A1 (en) * 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Chimeric antigens
PL2540312T3 (pl) * 2007-07-19 2015-10-30 Novavax Inc Chimeryczne VLP ptasiej grypy
EA021393B1 (ru) * 2007-12-24 2015-06-30 Глаксосмитклайн Байолоджикалс С.А. Рекомбинантные антигены rsv
EP2254554A1 (en) * 2008-02-25 2010-12-01 Novavax, Inc. Sugar glassified virus like particles (vlps)
KR101027159B1 (ko) * 2008-07-28 2011-04-05 뮤추얼아이피서비스(주) 타겟 영상 검출 장치 및 그 방법
WO2010077712A1 (en) * 2008-12-09 2010-07-08 Novavax, Inc. Bovine respiratory syncytial virus virus-like particle (vlps)
LT3067064T (lt) * 2008-12-09 2020-09-10 Novavax, Inc. Modifikuoti rsv f baltymai ir jų panaudojimo būdai

Also Published As

Publication number Publication date
US20150306207A1 (en) 2015-10-29
IL231637A0 (en) 2014-05-28
CN105381457A (zh) 2016-03-09
US20170319682A1 (en) 2017-11-09
EP2760469A4 (en) 2015-03-18
BR112014007616A2 (pt) 2017-04-04
EP2760469A1 (en) 2014-08-06
KR20140077169A (ko) 2014-06-23
JP2014530010A (ja) 2014-11-17
SG11201400999VA (en) 2014-07-30
WO2013049342A1 (en) 2013-04-04
RU2014117068A (ru) 2015-11-10
MX2014003777A (es) 2015-05-15
US20150335730A1 (en) 2015-11-26
AU2013201495A1 (en) 2013-04-18
CA2849471A1 (en) 2013-04-04
US20130122032A1 (en) 2013-05-16
CN104080476A (zh) 2014-10-01
AU2013201495B2 (en) 2015-12-03
HK1222125A1 (zh) 2017-06-23

Similar Documents

Publication Publication Date Title
HK1222125A1 (zh) 用於呼吸道合胞病毒的重組納米顆粒 疫苗
SG10201801431TA (en) Respiratory syncytial virus (rsv) vaccine
EP2780065A4 (en) NASALMASKENSYSTEM
GB2490507C (en) Respiratory mask
EP2776107A4 (en) EXCHANGER ASSEMBLY FOR THE TREATMENT OF RESPIRATORY WAYS
AP2014007993A0 (en) Vaccine against RSV
HK1202442A1 (en) Vaccines against hpv hpv
EP2806891A4 (en) PARAIN FLUENZA VIRUS 5 BASED VACCINES
HK1189884A1 (zh) 用於治療呼吸道合胞病毒感染的化合物
EP2716319A4 (en) Laryngeal
EP2753354A4 (en) SUBUNIT VACCINE AGAINST NANOEMULSION SYNCYTIAL RESPIRATORY VIRUS (RSV)
PL2755680T3 (pl) Preparaty szczepionkowe w postaci cząstek
ZA201405177B (en) Vesicular stomatitis virus for prime boost vaccines
IL221320A0 (en) Compounds for treating respiratory syncytial virus infections
HK1223644A1 (zh) 呼吸道合胞病毒半活疫苗
AU339730S (en) Respiratory mask
EP2678043A4 (en) RECOMBINANT MUMPSVIRUS VACCINE
HK1223643A1 (zh) 呼吸道合胞病毒半活疫苗
HUP1100470A2 (en) Nanoparticle-based veterinary vaccine
EP2739629A4 (en) COMPOUNDS FOR THE TREATMENT OF SYNCYTIAL RESPIRATORY VIRUS INFECTIONS
TWM432433U (en) Respiratory nasal tube
EP2752199A4 (en) RSV MUCOSA VACCINE
HK1206272A1 (en) Vaccine against rsv rsv